Zhithong Finance APP News, Hainan Huluwa Pharmaceutical Group (605199.SH) announced that the company recently received the approval and issuance of the National Medical Products Administration regarding the 'Drug Registration Certificate' for the Agaruban Injection. The indications for Agaruban Injection are: 1. For the improvement of neurological symptoms (motor paralysis) and daily activities (walking, standing, sitting posture maintenance, eating) of patients with acute ischemic stroke within 48 hours of onset. 2. For the improvement of limb ulcers, rest pain, and cold sensation in patients with chronic arterial occlusive disease (thromboangiitis obliterans, atherosclerosis obliterans).

Agaruban Injection is a Class B variety in the 'National Basic Medical Insurance, Work-related Injury Insurance, and Maternity Insurance Pharmaceutical List (2023 Edition).' The company's approved drug is evaluated and approved based on consistent technical requirements in terms of quality and efficacy with the reference preparation, and after approval, it is considered to have passed the consistency evaluation of generic drug quality and efficacy.